Prognostic value of C-reactive protein to albumin ratio for mortality in acute kidney injury

Liu, Baohua; Lv, Dezhao

doi:10.1186/s12882-023-03090-9

Cited by 9 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During normal conditions, OPN is present in the loop of Henle and in the nephrons of the kidneys. After renal damage, significant expression of OPN may be observed in the urine as a result of tubular and glomerular deterioration [ 147 , 148 , 149 ]. In this line, it is important to mention that OPN function is also related to inhibition of bone mineralization, more specifically in prevention of kidney stone formation [ 148 ].…”

Section: Resultsmentioning

confidence: 99%

Recent Advances of Proteomics in Management of Acute Kidney Injury

Pejchinovski¹,

Türkkan²,

Pejchinovski

2023

Diagnostics

View full text Add to dashboard Cite

Acute Kidney Injury (AKI) is currently recognized as a life-threatening disease, leading to an exponential increase in morbidity and mortality worldwide. At present, AKI is characterized by a significant increase in serum creatinine (SCr) levels, typically followed by a sudden drop in glomerulus filtration rate (GFR). Changes in urine output are usually associated with the renal inability to excrete urea and other nitrogenous waste products, causing extracellular volume and electrolyte imbalances. Several molecular mechanisms were proposed to be affiliated with AKI development and progression, ultimately involving renal epithelium tubular cell-cycle arrest, inflammation, mitochondrial dysfunction, the inability to recover and regenerate proximal tubules, and impaired endothelial function. Diagnosis and prognosis using state-of-the-art clinical markers are often late and provide poor outcomes at disease onset. Inappropriate clinical assessment is a strong disease contributor, actively driving progression towards end stage renal disease (ESRD). Proteins, as the main functional and structural unit of the cell, provide the opportunity to monitor the disease on a molecular level. Changes in the proteomic profiles are pivotal for the expression of molecular pathways and disease pathogenesis. Introduction of highly-sensitive and innovative technology enabled the discovery of novel biomarkers for improved risk stratification, better and more cost-effective medical care for the ill patients and advanced personalized medicine. In line with those strategies, this review provides and discusses the latest findings of proteomic-based biomarkers and their prospective clinical application for AKI management.

show abstract

Section: Resultsmentioning

confidence: 99%

Recent Advances of Proteomics in Management of Acute Kidney Injury

Pejchinovski¹,

Türkkan²,

Pejchinovski

2023

Diagnostics

View full text Add to dashboard Cite

show abstract

“…However, these results are less consistent. Therefore, compared to individual inflammatory markers, the CRP/ albumin ratio (CAR) is a well-established and more sensitive composite index of systemic inflammation [13][14][15]. In addition, CAR is a standalone predictor of short-term mortality in several diseases [13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, compared to individual inflammatory markers, the CRP/ albumin ratio (CAR) is a well-established and more sensitive composite index of systemic inflammation [13][14][15]. In addition, CAR is a standalone predictor of short-term mortality in several diseases [13][14][15][16]. According to several studies, higher CAR values in patients with stroke are linked to mortality or other adverse outcomes during the acute phase [17,18].…”

Section: Introductionmentioning

confidence: 99%

Dose-Response Relationship between C-Reactive Protein/Albumin Ratio and In-Hospital Mortality in Elderly Patients with Acute Ischemic Stroke

Li,

Chen,

Chen

et al. 2023

Gerontology

View full text Add to dashboard Cite

Introduction: The C-reactive protein/albumin ratio is a reliable indicator of outcome risk in several diseases. This study aims to evaluate prognostic power of the C-reactive protein/albumin ratio for in-hospital mortality and the dose-response relationship between the two in the oldest-old patients with acute ischemic stroke. Methods: A longitudinal observational study was conducted including patients with acute ischemic stroke (aged ≥ 80 years) from two tertiary hospitals between January 1, 2014, and January 31, 2020. Based on the tertiles of the C-reactive protein/albumin ratio, the patients were divided into three groups. Restrictive cubic spline and robust locally weighted regression analysis were performed on continuous variables to examine the dose–response relationship between the C-reactive protein/albumin ratio and in-hospital mortality risk. All-cause mortality during hospitalization was the outcome for this study. Results: The study included 584 patients (mean age = 84.6 ± 3.1 years; 59.6% men). The C-reactive protein/albumin ratio was divided into three groups, namely, T1 of < 0.73, T2 of 0.73 – 2.03, and T3: > 2.03. After adjusting for demographic and clinical characteristics, a higher C-reactive protein/albumin ratio was independently associated with in-hospital mortality. The hazard ratio for this association was 2.01 (95% confidence interval: 1.12 – 3.60, P = 0.019). A dose–response relationship between the C-reactive protein/albumin ratio and in-hospital mortality risk was observed. Sensitivity analysis found no attenuation in the hazard ratio in uninfected individuals, whereas no difference in the hazard ratio was noted in individuals with infections. Conclusions: When predicting in–hospital mortality in the oldest-old patients with ischemic stroke, the C-reactive protein/albumin ratio might be a helpful and convenient metric.

show abstract